Seer Revenue 2021-2022 | SEER
Seer revenue from 2021 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
| Seer Annual Revenue (Millions of US $) |
|
|---|---|
| 2021 | $ |
| 2020 | $ |
| Seer Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2022-03-31 | |
| 2021-12-31 | |
| 2021-09-30 | |
| 2021-06-30 | |
| 2021-03-31 | |
| 2020-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.468B | $0.007B |
| Seer Inc. is a life sciences company. It engages in developing Proteograph(TM), which is an integrated solution consisting of consumables, automation instrumentation and proprietary software. Seer Inc. is based in REDWOOD CITY, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $164.449B | 10.01 |
| Bio-Rad Laboratories (BIO.B) | United States | $15.121B | 32.79 |
| QIAGEN (QGEN) | Netherlands | $10.298B | 16.25 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.114B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $5.068B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $1.695B | 7.26 |
| Arcus Biosciences (RCUS) | United States | $1.307B | 33.13 |
| Myovant Sciences (MYOV) | United Kingdom | $0.933B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.493B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.348B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.342B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.162B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.112B | 23.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.094B | 0.00 |
